指南与共识泌尿男性生殖肿瘤支持与姑息治疗

EAU-ESMO晚期及变异型膀胱癌管理共识声明

EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†.
指南 / 共识 · Ann Oncol · 2019-01-01

该共识由EAU和ESMO联合组织113名专家通过Delphi调查和共识会议制定,针对晚期及变异型膀胱癌管理中的争议话题。116条声明中33条(28%)达到一级共识,49条(42%)达到一级或二级共识;共识会议中27条声明有22条(81%)达成共识。共识涵盖变异组织学管理、预后生物标志物、膀胱保留策略、现代放疗、寡转移性疾病及免疫检查点抑制剂治疗等。

要点

  • 116条声明中仅33条(28%)达一级共识,49条(42%)达一级或二级共识。
  • 共识会议27条声明中22条(81%)达成共识。
  • 共识涉及变异组织学、生物标志物、膀胱保留、放疗、寡转移及免疫治疗。

核心结论

  • 共识声明为晚期及变异型膀胱癌管理中的争议话题提供进一步指导,直至有更多证据可用。

研究设计与样本

  • 由指导委员会编制关于晚期及变异型膀胱癌管理的声明,经113名专家Delphi调查评估。
  • 未达共识的声明经审查后,优先条目由45名专家小组修订并在共识会议投票。
  • 共识定义为≥70%同意且≤15%不同意,或反之;二级共识限制于相关利益专家组分析。

主要发现

  • Delphi调查纳入116条声明,33条(28%)达一级共识,49条(42%)达一级或二级共识。
  • 共识会议中27条声明有22条(81%)达成共识。

关键数值与推荐

  • 共识阈值:一级共识为≥70%同意且≤15%不同意,或反之。
  • Delphi调查116条声明中33条(28%)达一级共识,49条(42%)达一级或二级共识。
  • 共识会议27条声明中22条(81%)达成共识。

临床怎么用

  • 共识声明可用于指导变异组织学、预后生物标志物、膀胱保留策略、现代放疗、寡转移性疾病及免疫检查点抑制剂治疗等临床决策。

局限性

  • 部分领域证据有限或存在冲突,最佳方法仍有争议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Horwich A, Babjuk M, Bellmunt J, et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. Ann Oncol. 2019. PMID: 31740927. doi:10.1093/annonc/mdz296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。